The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.

The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide. - The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024859

Enrollment

Registered

2016-11-16

Start date

2016-12-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Switching from Dopamine agonist to Zonisamide. Intervention period of 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1)Patients who have taken zonisamide within 6 months from the start of study drug administration 2)Patients with cognitive impairment of MMSE score 23 or less 3)Patients who have undergone surgical therapy for parkinsonism, including stereotactic neurosurgery 4)Pregnant or possibly pregnant women, women of childbearing potential who do not agree to use appropriate contraceptive measures, or breast-feeding women 5)Patients who, in the opinion of the investigator or other study personnel, are unsuitable for the study

Design outcomes

Primary

Measure	Time frame
Change in the MDS-UPDRS Part III (motor symptoms) total score at 12 weeks and change in the MDS-UPDRS Part 1.2 (hallucinations and psychosis) score at 12 weeks	—

Secondary

Measure	Time frame
1)Change in the MDS-UPDRS Part1 (non-motor symptoms except Part 1.2) total score, change in the MDS-UPDRS Part 2(motor aspects) total score, and change in the MDS-UPDRS Part 4 (motor complications) total score 2)Change in the BDI-2(depression)total score 3)Change in the JESS(sleepiness)total score 4)Change in the J-ZBI(burden of caregiver) total score 5)Change in the NPI(BPSD) total score 6)Change in the MMSE(cognitive function)total score	—

Measure

Time frame

1)Change in the MDS-UPDRS Part1 (non-motor symptoms except Part 1.2) total score, change in the MDS-UPDRS Part 2(motor aspects) total score, and change in the MDS-UPDRS Part 4 (motor complications) total score 2)Change in the BDI-2(depression)total score 3)Change in the JESS(sleepiness)total score 4)Change in the J-ZBI(burden of caregiver) total score 5)Change in the NPI(BPSD) total score 6)Change in the MMSE(cognitive function)total score

—

Countries

Japan

Contacts

Public ContactKeigo Nakajima

EP-CRSU Co. Ltd. (Contract Research Organization) Clinical Research Headquarters

TRF@eps.co.jp03-5684-7809

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

The effectiveness of motor and psychiatric symptoms for Parkinson&#39;s disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.